Literature DB >> 3545524

Flavone acetic acid (LM 975, NSC 347512). A novel antitumor agent.

P J O'Dwyer, D Shoemaker, D S Zaharko, C Grieshaber, J Plowman, T Corbett, F Valeriote, S A King, J Cradock, D F Hoth.   

Abstract

Flavone acetic acid (FAA) is a synthetic flavonoid compound which has recently begun clinical trials as an antitumor agent based on its striking activity in solid tumor model systems. The pharmacologic behavior of FAA in animals appears to be predictive of both its cytotoxic efficacy and its toxicity to normal tissues (principally the central nervous system and gastrointestinal tract). The design and conduct of phase I studies in man are based upon these principles, with the goal of maximizing their safety and efficacy.

Entities:  

Mesh：

Substances：

Year:  1987        PMID： 3545524     DOI： 10.1007/BF00296246

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  9 in total

1.  Relation between the chemical constitution and the pharmacological action, especially on the coronary vessels of the heart, of some synthesized pyrones and khellin.

Authors:  G JONGEBREUR
Journal:  Arch Int Pharmacodyn Ther       Date:  1952

2.  Flavoxate, a potent phosphodiesterase inhibitor.

Authors:  M Conti; I Setnikar
Journal:  Arch Int Pharmacodyn Ther       Date:  1975-02

3.  Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors.

Authors:  D S Zaharko; C K Grieshaber; J Plowman; J C Cradock
Journal:  Cancer Treat Rep       Date:  1986-12

4.  Pharmacological studies on the mode of action of flavoxate.

Authors:  P Cazzulani; R Panzarasa; C Luca; D Oliva; G Graziani
Journal:  Arch Int Pharmacodyn Ther       Date:  1984-04

5.  Activity of flavone acetic acid (NSC-347512) against solid tumors of mice.

Authors:  T H Corbett; M C Bissery; A Wozniak; J Plowman; L Polin; E Tapazoglou; J Dieckman; F Valeriote
Journal:  Invest New Drugs       Date:  1986       Impact factor: 3.850

6.  Interaction between quercetin and Ca2+-calmodulin complex: possible mechanism for anti-tumor-promoting action of the flavonoid.

Authors:  H Nishino; E Naito; A Iwashima; K Tanaka; T Matsuura; H Fujiki; T Sugimura
Journal:  Gan       Date:  1984-04

7.  Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice.

Authors:  J Plowman; V L Narayanan; D Dykes; E Szarvasi; P Briet; O C Yoder; K D Paull
Journal:  Cancer Treat Rep       Date:  1986-05

Review 8.  Flavonoids, a class of natural products of high pharmacological potency.

Authors:  B Havsteen
Journal:  Biochem Pharmacol       Date:  1983-04-01       Impact factor: 5.858

9.  Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).

Authors:  D J Kerr; S B Kaye; J Graham; J Cassidy; M Harding; A Setanoians; J C McGrath; W R Vezin; D Cunningham; G Forrest
Journal:  Cancer Res       Date:  1986-06       Impact factor: 12.701
  9 in total
  11 in total

1.  Preclinical antitumor activity of batracylin (NSC 320846).

Authors:  J Plowman; K D Paull; G Atassi; S D Harrison; D J Dykes; H J Kabbe; V L Narayanan; O C Yoder
Journal:  Invest New Drugs       Date:  1988-09       Impact factor: 3.850

2.  Combination of flavone acetic acid (FAA) with adriamycin, cis-platinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells.

Authors:  S S Neelam; A Bernabei; C Freedland; R Thompson; T H Corbett; G D Luk
Journal:  Invest New Drugs       Date:  1990-08       Impact factor: 3.850

3.  Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice.

Authors:  G G Chabot; M C Bissery; T H Corbett; K Rutkowski; L H Baker
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

Review 4.  Flavone 8-acetic acid: our current understanding of its mechanism of action in solid tumours.

Authors:  J Cummings; J F Smyth
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

5.  Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.

Authors:  M J McKeage; P Kestell; W A Denny; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

6.  Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.

Authors:  L M Ching; M J McKeage; W R Joseph; P Kestell; L J Zwi; B C Baguley
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

7.  Saturable elimination and saturable protein binding account for flavone acetic acid pharmacokinetics.

Authors:  M V Relling; R R Evans; S Groom; W R Crom; C B Pratt
Journal:  J Pharmacokinet Biopharm       Date:  1993-12

8.  Dose-dependent pharmacokinetics of flavone acetic acid in mice.

Authors:  G Damia; M L Zanette; C Rossi; R Mandelli; A Ferrari; M D'Incalci
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

9.  Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).

Authors:  M Philpott; W R Joseph; K E Crosier; B C Baguley; L M Ching
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

10.  Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.

Authors:  M B Jameson; P I Thompson; B C Baguley; B D Evans; V J Harvey; D J Porter; M R McCrystal; M Small; K Bellenger; L Gumbrell; G W Halbert; P Kestell
Journal:  Br J Cancer       Date:  2003-06-16       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.